The interplay between cancer cells and the immune system is a critical area of research, with recent advancements highlighting the potential of immunotherapy in offering durable responses across various cancer types. Immune checkpoint inhibitors, in particular, have emerged as a cornerstone of cancer therapy, transforming patient outcomes. However, the heterogeneity of tumor-immune interactions poses significant challenges, with a considerable fraction of patients not responding to such treatments. This underscores the urgent need for a deeper understanding of the molecular and cellular underpinnings of these interactions, to harness the full potential of immunotherapy.
This Research Topic aims to address the complex landscape of tumor-immune interactions, focusing on identifying and leveraging novel biomarkers and mechanisms that can predict and enhance the efficacy of immunotherapy. Given the pivotal role of the immune system in controlling and eradicating cancer, understanding these interactions at a granular level could lead to more personalized and effective treatment strategies. Recent advances in technologies such as next-generation sequencing, single-cell RNA sequencing, and mass cytometry have opened new avenues for dissecting the complexity of the tumor microenvironment and immune evasion strategies. This collection seeks to compile cutting-edge research that employs these technologies to uncover new biomarkers, understand resistance mechanisms, and identify potential therapeutic targets within the immune contexture of tumors. By bridging gaps in knowledge and fostering innovation, this topic aims to propel the field towards more predictive and responsive immunotherapy approaches.
We welcome Original Research, Review Articles, Case Studies, and Methodological advancements that provide significant insights into a wide range of themes related to tumor-immune interactions and immunotherapy. Specifically, we are looking for:
• Novel biomarkers of immunotherapy response or resistance.
• Mechanistic insights into tumor-immune evasion.
• The impact of the tumor microenvironment on immunotherapy outcomes.
• Advances in technologies for profiling tumor-immune interactions.
• Therapeutic strategies targeting the immune system in cancer.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The interplay between cancer cells and the immune system is a critical area of research, with recent advancements highlighting the potential of immunotherapy in offering durable responses across various cancer types. Immune checkpoint inhibitors, in particular, have emerged as a cornerstone of cancer therapy, transforming patient outcomes. However, the heterogeneity of tumor-immune interactions poses significant challenges, with a considerable fraction of patients not responding to such treatments. This underscores the urgent need for a deeper understanding of the molecular and cellular underpinnings of these interactions, to harness the full potential of immunotherapy.
This Research Topic aims to address the complex landscape of tumor-immune interactions, focusing on identifying and leveraging novel biomarkers and mechanisms that can predict and enhance the efficacy of immunotherapy. Given the pivotal role of the immune system in controlling and eradicating cancer, understanding these interactions at a granular level could lead to more personalized and effective treatment strategies. Recent advances in technologies such as next-generation sequencing, single-cell RNA sequencing, and mass cytometry have opened new avenues for dissecting the complexity of the tumor microenvironment and immune evasion strategies. This collection seeks to compile cutting-edge research that employs these technologies to uncover new biomarkers, understand resistance mechanisms, and identify potential therapeutic targets within the immune contexture of tumors. By bridging gaps in knowledge and fostering innovation, this topic aims to propel the field towards more predictive and responsive immunotherapy approaches.
We welcome Original Research, Review Articles, Case Studies, and Methodological advancements that provide significant insights into a wide range of themes related to tumor-immune interactions and immunotherapy. Specifically, we are looking for:
• Novel biomarkers of immunotherapy response or resistance.
• Mechanistic insights into tumor-immune evasion.
• The impact of the tumor microenvironment on immunotherapy outcomes.
• Advances in technologies for profiling tumor-immune interactions.
• Therapeutic strategies targeting the immune system in cancer.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
